Immunology Phase 3 Readout Calendar

Industry-sponsored immunology trials with primary completion in the next 12 months or last 12 months.

Data last updated November 12, 2026 · source: ClinicalTrials.gov

Pro feature

All areas OncologyImmunologyMetabolic CNS Cardiovascular Respiratory Rare Disease Infectious Disease Musculoskeletal Dermatology Ophthalmology

Next 6 months

Next 12 months

Results posted

361

Phase 3 Immunology

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 immunology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.

What immunology trials are reading out soon?

The "upcoming" section shows industry-sponsored Phase 3 immunology trials with primary completion ahead, soonest first, each graded by how credible that date is.

Which immunology trials have already read out?

The "recently read out" section shows Phase 3 immunology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.

How are these readout dates sourced?

Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.

Where can I see readouts for other therapeutic areas?

The full cross-area calendar is on the main readout calendar; this page is the Immunology slice of it.

Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Immunology landscape →

Recently read out & awaiting topline — Immunology

· 13

Phase 3 immunology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
UCB Biopharma SRL	A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis Asset: Certolizumab pegol	Moderate Chronic Plaque Psoriasis +2	Completed	Q2 2026 2026-04-09	Completed · awaiting Updated 7mo ago	NCT04123795
Eli Lilly and Company	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Asset: Mirikizumab	Ulcerative Colitis	Active Not Recruiting	Q1 2026 2026-03-04	Completed · awaiting Updated 7mo ago	NCT03519945
Celltrion	A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis Asset: CT-P55	Plaque Psoriasis	Active Not Recruiting	Q1 2026 2026-02-18	Completed · awaiting Updated 9mo ago	NCT06630559
UCB Biopharma SRL	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Asset: Bimekizumab	Psoriatic Arthritis	Completed	Q1 2026 2026-02-06	Completed · awaiting Updated 7mo ago	NCT06624228
Sun Pharmaceutical Industries Limi…	A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Asset: Tildrakizumab 100 mg	Moderate to Severe Genital Psoriasis	Active Not Recruiting	Q1 2026 2026-01-21	Completed · awaiting Updated 8mo ago	NCT06611163
Eli Lilly and Company	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab	Atopic Dermatitis +1	Active Not Recruiting	Q1 2026 2026-01-14	Completed · awaiting Updated 10mo ago	NCT05559359
Eli Lilly and Company	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab	Psoriasis +1	Completed	Q1 2026 2026-01-08	Completed · awaiting Updated 10mo ago	NCT06588283
Alexion Pharmaceuticals, Inc.	Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Asset: Ravulizumab	Immunoglobulin A Nephropathy +1	Active Not Recruiting	Q1 2026 2026-01-05	Completed · awaiting Updated 7mo ago	NCT06291376
Alexion Pharmaceuticals, Inc.	Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Asset: Eculizumab	Generalized Myasthenia Gravis (gMG) +1	Completed	Q4 2025 2025-12-29	Completed · awaiting Updated 10mo ago	NCT06764160
Pfizer	Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Asset: Abrocitinib 100 mg	Dermatitis, Atopic	Completed	Q4 2025 2025-12-22	Completed · awaiting Updated 10mo ago	NCT03422822
Amgen	A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Asset: Apremilast	Plaque Psoriasis	Completed	Q4 2025 2025-11-20	Completed · awaiting Updated 11mo ago	NCT05565560
Eli Lilly and Company	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab	Psoriatic Arthritis +1	Completed	Q4 2025 2025-11-18	Completed · awaiting Updated 10mo ago	NCT06588296
Janssen Research & Development, LLC	A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis Asset: JNJ-77242113	Plaque Psoriasis	Active Not Recruiting	Q4 2025 2025-11-17	Completed · awaiting Updated 7mo ago	NCT06934226

Upcoming immunology readouts — next 12 months

· 83

Industry Phase 3 immunology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
AstraZeneca	A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus	Cutaneous Lupus Erythematosus	Active Not Recruiting	Q4 2026 2026-11-13 (est.)	Estimated · aging Updated 8mo ago	NCT06015737
UCB Biopharma SRL	A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Asset: Zilucoplan	Generalized Myasthenia Gravis	Recruiting	Q4 2026 2026-11-16 (est.)	Estimated · aging Updated 7mo ago	NCT06055959
Bristol-Myers Squibb	A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Asset: Deucravacitinib	Sjögren's Syndrome	Active Not Recruiting	Q4 2026 2026-11-18 (est.)	Estimated · aging Updated 7mo ago	NCT05946941
Beijing InnoCare Pharma Tech Co., …	ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis Asset: ICP-332 Tablets	Atopic Dermatitis	Recruiting	Q4 2026 2026-11-25 (est.)	Estimated · stale Updated 14mo ago	NCT06775860
Wooshin Labottach Co., Ltd.	Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis	Nail Psoriasis +2	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 10mo ago	NCT07029516
Lynk Pharmaceuticals Co., Ltd	A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis Asset: LNK01001	Ankylosing Spondylitis	Recruiting	Q4 2026 2026-11 (est.)	Estimated · aging Updated 12mo ago	NCT07237568
medac GmbH	Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. Asset: Methotrexate	Moderate to Severe Atopic Dermatitis	Recruiting	Q4 2026 2026-11 (est.)	Estimated · stale Updated 15mo ago	NCT06239311
Tasly Pharmaceutical Group Co., Ltd	A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo Asset: Jitongning tablets	Ankylosing Spondylitis	Recruiting	Q4 2026 2026-12-01 (est.)	Estimated · stale Updated 24mo ago	NCT06000956
Alexion Pharmaceuticals, Inc.	Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD Asset: eculizumab	NMOSD +1	Active Not Recruiting	Q4 2026 2026-12-07 (est.)	Estimated · aging Updated 11mo ago	NCT06724809
Alexion Pharmaceuticals, Inc.	PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis	Generalized Myasthenia Gravis +1	Recruiting	Q4 2026 2026-12-15 (est.)	Estimated · aging Updated 7mo ago	NCT06607627
Novartis Pharmaceuticals	Atrasentan in Patients With IgA Nephropathy Asset: Atrasentan	IgA Nephropathy +1	Active Not Recruiting	Q4 2026 2026-12-18 (est.)	Estimated · stale Updated 25mo ago	NCT04573478
UCB Biopharma SRL	A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa Asset: Bimekizumab	Hidradenitis Suppurativa	Active Not Recruiting	Q4 2026 2026-12-21 (est.)	Estimated · aging Updated 8mo ago	NCT06921850
Incyte Corporation	A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Asset: Povorcitinib	Hidradenitis Suppurativa (HS)	Active Not Recruiting	Q4 2026 2026-12-26 (est.)	Estimated · aging Updated 8mo ago	NCT06212999
Jiangsu Topcel-KH Pharmaceutical C…	Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease	Crohn's Disease	Recruiting	Q4 2026 2026-12-28 (est.)	Estimated · stale Updated 19mo ago	NCT06925594
RemeGen Co., Ltd.	A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) Asset: Telitacicept	Myasthenia Gravis, Ocular	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · aging Updated 7mo ago	NCT07249632
AbbVie	A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Asset: Lutikizumab	Hidradenitis Suppurativa	Active Not Recruiting	Q4 2026 2026-12 (est.)	Estimated · aging Updated 8mo ago	NCT06468228
Otsuka Pharmaceutical Co., Ltd.	A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis Asset: OPA-15406	Atopic Dermatitis (AD)	Not Yet Recruiting	Q4 2026 2026-12 (est.)	Estimated · stale Updated 14mo ago	NCT07173478
Hangzhou Highlightll Pharmaceutica…	A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis Asset: TLL-018	Rheumatoid Arthritis	Active Not Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · stale Updated 20mo ago	NCT06887127
Biocity Biopharmaceutics Co., Ltd.	A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria Asset: SC0062 strength 10mg	IgA Nephropathy (IgAN)	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · stale Updated 21mo ago	NCT06819826
Shanghai Mabgeek Biotech.Co.Ltd	A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis Asset: MG-K10 Injection (Humanized Monoclonal Antibody)	Dermatitis, Atopic	Not Yet Recruiting	Q1 2027 2027-01-05 (est.)	Estimated · aging Updated 7mo ago	NCT07540442
Sunshine Guojian Pharmaceutical (S…	A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) Asset: 608 dose	Ankylosing Spondylitis	Recruiting	Q1 2027 2027-01-14 (est.)	Estimated · aging Updated 11mo ago	NCT07261644
MoonLake Immunotherapeutics AG	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Asset: Sonelokimab	Arthritis, Psoriatic	Active Not Recruiting	Q1 2027 2027-01-15 (est.)	Estimated · aging Updated 7mo ago	NCT06641089
Hoffmann-La Roche	A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart	Moderately to Severely Active Ulcerative Colitis	Active Not Recruiting	Q1 2027 2027-01-30 (est.)	Estimated · aging Updated 7mo ago	NCT06588855
Hoffmann-La Roche	A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart	Moderately to Severely Active Ulcerative Colitis	Active Not Recruiting	Q1 2027 2027-01-30 (est.)	Estimated · aging Updated 8mo ago	NCT06589986
Reistone Biopharma Company Limited	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. Asset: RSS0393 ointment 0.03%	Plaque Psoriasis Subjects	Not Yet Recruiting	Q1 2027 2027-01 (est.)	Estimated · aging Updated 7mo ago	NCT07543224
AbbVie	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis Asset: Placebo	Atopic Dermatitis	Active Not Recruiting	Q1 2027 2027-01 (est.)	Estimated · aging Updated 9mo ago	NCT06701331
MoonLake Immunotherapeutics AG	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug Asset: Sonelokimab	Arthritis, Psoriatic	Active Not Recruiting	Q1 2027 2027-02-04 (est.)	Estimated · aging Updated 7mo ago	NCT06641076
Janssen Research & Development, LLC	A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis Asset: Icotrokinra	Arthritis, Psoriatic	Active Not Recruiting	Q1 2027 2027-02-10 (est.)	Estimated · aging Updated 7mo ago	NCT06807424
Novartis Pharmaceuticals	A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Asset: Remibrutinib	Chronic Spontaneous Urticaria (CSU)	Active Not Recruiting	Q1 2027 2027-02-22 (est.)	Estimated · aging Updated 8mo ago	NCT06868212
AstraZeneca	Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis Asset: Anifrolumab	Lupus Nephritis	Active Not Recruiting	Q1 2027 2027-02-26 (est.)	Estimated · aging Updated 9mo ago	NCT05138133
Otsuka Pharmaceutical Co., Ltd.	A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis Asset: OPA-15406	Atopic Dermatitis (AD)	Not Yet Recruiting	Q1 2027 2027-02 (est.)	Estimated · stale Updated 14mo ago	NCT07184645
Keymed Biosciences Co.Ltd	A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis Asset: Stapokibatrt	Atopic Dermatitis	Not Yet Recruiting	Q1 2027 2027-02 (est.)	Estimated · stale Updated 15mo ago	NCT07106372
Institut Pasteur	Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients Asset: ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy	Hidradenitis Suppurativa	Recruiting	Q1 2027 2027-02-28 (est.)	Estimated · stale Updated 16mo ago	NCT05821478
UCB Biopharma SRL	A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis Asset: bimekizumab	Moderate to Severe Plaque Psoriasis +1	Active Not Recruiting	Q1 2027 2027-03-09 (est.)	Estimated · aging Updated 7mo ago	NCT06506916
Novartis Pharmaceuticals	Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) Asset: Ianalumab	Systemic Lupus Erythematosus	Active Not Recruiting	Q1 2027 2027-03-24 (est.)	Estimated · aging Updated 8mo ago	NCT05639114
Janssen-Cilag Ltd.	A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease Asset: Guselkumab	Fistulizing Crohns Disease +1	Active Not Recruiting	Q1 2027 2027-03-25 (est.)	Estimated · aging Updated 7mo ago	NCT05347095
Hoffmann-La Roche	A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) Asset: Satralizumab	Neuromyelitis Optica Spectrum Disorder +1	Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · aging Updated 7mo ago	NCT05199688
AbbVie	Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus Asset: Upadacitinib	Systemic Lupus Erythematosus	Active Not Recruiting	Q1 2027 2027-03 (est.)	Estimated · aging Updated 8mo ago	NCT05843643
argenx	Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Asset: Efgartigimod IV	Generalized Myasthenia Gravis	Active Not Recruiting	Q1 2027 2027-03 (est.)	Estimated · aging Updated 9mo ago	NCT04833894
AbbVie	A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. Asset: Risankizumab SC	Crohn's Disease	Active Not Recruiting	Q1 2027 2027-03 (est.)	Estimated · stale Updated 14mo ago	NCT06063967
Qilu Pharmaceutical Co., Ltd.	Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis Asset: 1.5% QLM3003 ointment	Atopic Dermatitis	Recruiting	Q1 2027 2027-03 (est.)	Estimated · stale Updated 15mo ago	NCT06880276
Hansoh BioMedical R&D Company	A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis Asset: HS-20137	Moderate-to-severe Plaque Psoriasis	Not Yet Recruiting	Q1 2027 2027-03-31 (est.)	Estimated · stale Updated 21mo ago	NCT06844799
Novartis Pharmaceuticals	Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Asset: Ianalumab	Systemic Lupus Erythematosus	Active Not Recruiting	Q2 2027 2027-04-12 (est.)	Estimated · aging Updated 8mo ago	NCT05624749
Almirall, S.A.	A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab	Dermatitis, Atopic +1	Active Not Recruiting	Q2 2027 2027-04-25 (est.)	Estimated · aging Updated 7mo ago	NCT06526182
Pfizer	Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis Asset: tofacitinib	Ulcerative Colitis	Active Not Recruiting	Q2 2027 2027-04-28 (est.)	Estimated · aging Updated 9mo ago	NCT04624230
CSPC Ouyi Pharmaceutical Co., Ltd.	A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis Asset: SYHX1901	Moderate to Severe Plaque Psoriasis	Not Yet Recruiting	Q2 2027 2027-04-28 (est.)	Estimated · stale Updated 18mo ago	NCT06943950
Novartis Pharmaceuticals	A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. Asset: Iptacopan	Generalized Myasthenia Gravis	Active Not Recruiting	Q2 2027 2027-04-30 (est.)	Estimated · aging Updated 7mo ago	NCT06517758
Jiangsu Genscend Biopharmaceutical…	A Phase III Study of GS101 Injection to Dupixent® Asset: GS101 injection	Atopic Dermatitis (AD)	Recruiting	Q2 2027 2027-04 (est.)	Estimated · aging Updated 9mo ago	NCT07386743
Pfizer	A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema Asset: Abrocitinib	Eczema	Recruiting	Q2 2027 2027-05-02 (est.)	Estimated · aging Updated 7mo ago	NCT06807268
Takeda	A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines Asset: Zasocitinib	Psoriatic Arthritis	Recruiting	Q2 2027 2027-05-18 (est.)	Estimated · aging Updated 7mo ago	NCT06671483
Takeda	A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines Asset: Zasocitinib	Psoriatic Arthritis	Active Not Recruiting	Q2 2027 2027-05-18 (est.)	Estimated · aging Updated 7mo ago	NCT06671496
E-nitiate Biopharmaceuticals (Hang…	A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. Asset: 10mg QY201 Placebo tablet	Atopic Dermatitis (AD)	Enrolling By Invitation	Q2 2027 2027-05-18 (est.)	Estimated · stale Updated 14mo ago	NCT07180511
Vor Biopharma	A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Asset: Telitacicept	Generalized Myasthenia Gravis	Active Not Recruiting	Q2 2027 2027-05 (est.)	Estimated · aging Updated 8mo ago	NCT06456580
Biogen	A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Asset: Felzartamab	Immunoglobulin A Nephropathy (IgAN)	Recruiting	Q2 2027 2027-05-31 (est.)	Estimated · aging Updated 7mo ago	NCT06935357
Qilu Pharmaceutical Co., Ltd.	A Phase Ⅲ Comparative Study of QL2108 to Dupixent® Asset: QL2108 injection	Atopic Dermatitis	Not Yet Recruiting	Q2 2027 2027-05 (est.)	Estimated · stale Updated 20mo ago	NCT06884891
Janssen-Cilag Ltd.	Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients Asset: Guselkumab	Crohn's Disease	Active Not Recruiting	Q2 2027 2027-06-08 (est.)	Estimated · aging Updated 7mo ago	NCT06408935
Takeda	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease Asset: Vedolizumab	Crohn's Disease	Recruiting	Q2 2027 2027-06-08 (est.)	Estimated · stale Updated 17mo ago	NCT06227910
Novartis Pharmaceuticals	Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis Asset: Ianalumab	Lupus Nephritis	Active Not Recruiting	Q2 2027 2027-06-22 (est.)	Estimated · aging Updated 8mo ago	NCT05126277
AbbVie	Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Asset: Upadacitinib	Crohn's Disease	Active Not Recruiting	Q2 2027 2027-06 (est.)	Estimated · aging Updated 7mo ago	NCT06332534
Takeda	A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Asset: Vedolizumab IV	Ulcerative Colitis +1	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · stale Updated 14mo ago	NCT06100289
Jemincare	Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. Asset: JYB1904	Chronic Spontaneous Urticaria	Recruiting	Q2 2027 2027-06-30 (est.)	Estimated · aging Updated 9mo ago	NCT07402213
Resilience	Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy	IBD	Not Yet Recruiting	Q2 2027 2027-06 (est.)	Estimated · stale Updated 16mo ago	NCT07043036
Qilu Pharmaceutical Co., Ltd.	A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis Asset: Voclosporin（QL1074）	Lupus Nephritis	Recruiting	Q2 2027 2027-06 (est.)	Estimated · stale Updated 30mo ago	NCT06406205
Akeso	A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis Asset: Placebo	Atopic Dermatitis	Not Yet Recruiting	Q3 2027 2027-07-10 (est.)	Estimated · stale Updated 22mo ago	NCT06767540
InventisBio Co., Ltd	A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis Asset: D-2570 Tablet	Plaque Psoriasis	Recruiting	Q3 2027 2027-07-12 (est.)	Estimated · aging Updated 7mo ago	NCT07326813
InventisBio Co., Ltd	Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis Asset: D-2570	Plaque Psoriasis	Recruiting	Q3 2027 2027-07-28 (est.)	Estimated · aging Updated 11mo ago	NCT07130604
AbbVie	A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Asset: Upadacitinib (ABT-494)	Ulcerative Colitis (UC)	Active Not Recruiting	Q3 2027 2027-07 (est.)	Estimated · aging Updated 10mo ago	NCT03006068
Bluefin Biomedicine, Inc.	A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa Asset: BFB759	Hidradenitis Suppurativa (HS)	Active Not Recruiting	Q3 2027 2027-08-01 (est.)	Estimated · aging Updated 7mo ago	NCT07287644
Novartis Pharmaceuticals	A Study of Zigakibart in Adults With IgA Nephropathy Asset: BION-1301	IgA Nephropathy +1	Active Not Recruiting	Q3 2027 2027-08-10 (est.)	Estimated · aging Updated 7mo ago	NCT05852938
UCB Biopharma SRL	An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis Asset: rozanolixizumab	Generalized Myasthenia Gravis	Active Not Recruiting	Q3 2027 2027-08-17 (est.)	Estimated · aging Updated 7mo ago	NCT06540144
Jiangsu vcare pharmaceutical techn…	Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. Asset: VC005 tablets	Active Ankylosing Spondylitis	Recruiting	Q3 2027 2027-08-30 (est.)	Estimated · aging Updated 10mo ago	NCT07172360
Jiangsu vcare pharmaceutical techn…	Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis Asset: VC005 low dose group	Moderate to Severe Atopic Dermatitis	Recruiting	Q3 2027 2027-08-30 (est.)	Estimated · stale Updated 21mo ago	NCT06723080
Novartis Pharmaceuticals	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) Asset: Remibrutinib Dose A	Hidradenitis Suppurativa	Active Not Recruiting	Q3 2027 2027-08-31 (est.)	Estimated · aging Updated 8mo ago	NCT06799000
Takeda	Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis Asset: Vedolizumab IV	Moderately to Severely Active Ulcerative Colitis	Active Not Recruiting	Q3 2027 2027-09-24 (est.)	Estimated · aging Updated 11mo ago	NCT03221036
Janssen Research & Development, LLC	Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis Asset: Nipocalimab	Myasthenia Gravis	Recruiting	Q3 2027 2027-09-28 (est.)	Estimated · aging Updated 7mo ago	NCT07217587
Janssen Research & Development, LLC	A Long-term Extension Study of Ustekinumab in Pediatric Participants Asset: Ustekinumab	Crohn Disease +2	Active Not Recruiting	Q3 2027 2027-09-29 (est.)	Estimated · aging Updated 7mo ago	NCT05092269
Kyverna Therapeutics	KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis Asset: Standard of Care Treatment	Myasthenia Gravis +1	Recruiting	Q3 2027 2027-09 (est.)	Estimated · aging Updated 7mo ago	NCT06193889
AbbVie	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 Asset: Upadacitinib	Crohn's Disease	Active Not Recruiting	Q3 2027 2027-09 (est.)	Estimated · aging Updated 7mo ago	NCT03345823
UCB Biopharma SRL	An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis Asset: Zilucoplan	Generalized Myasthenia Gravis	Enrolling By Invitation	Q4 2027 2027-10-26 (est.)	Estimated · aging Updated 7mo ago	NCT06435312
Janssen Research & Development, LLC	A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease Asset: Guselkumab	Crohn's Disease	Recruiting	Q4 2027 2027-10-27 (est.)	Estimated · aging Updated 7mo ago	NCT05923073
Novartis Pharmaceuticals	A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa Asset: Remibrutinib Dose A	Hidradenitis Suppurativa	Active Not Recruiting	Q4 2027 2027-10-29 (est.)	Estimated · aging Updated 8mo ago	NCT06840392
Shanghai Jiaolian Drug Research an…	A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) Asset: B001	Neuromyelitis Optica Spectrum Disorders	Recruiting	Q4 2027 2027-10-31 (est.)	Estimated · stale Updated 22mo ago	NCT06413654
Chengdu Suncadia Medicine Co., Ltd.	A Trial of HRS-5965 Capsule in Primary IgA Nephropathy Asset: HRS-5965	Primary IgA Nephropathy	Recruiting	Q4 2027 2027-10 (est.)	Estimated · stale Updated 15mo ago	NCT07014826

Unlock 73 more immunology readouts · plus filters on the full calendar

Upgrade to Pro

About this calendar

Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.